Fibrinolytic therapy, also termed thrombolytic therapy, is a medical strategy designed to dissolve blood clots within the vascular system. The formation of blood clots, or thrombi, poses significant health threats by obstructing blood vessels and giving rise to conditions like pulmonary embolism or deep vein thrombosis. Utilizing fibrinolytic agents, such as tissue plasminogen activator (tPA), this intervention facilitates the breakdown of fibrin, a key protein in blood clot formation. The administration of fibrinolytic therapy is particularly time-critical, especially in acute scenarios such as pulmonary embolism, where prompt action can prevent or mitigate severe consequences. Despite its effectiveness, fibrinolytic therapy is not without risks, with potential complications including bleeding. Consequently, its application is judiciously weighed against individual patient factors and the specific clinical context. As medical research advances, ongoing exploration seeks to refine approaches, aiming to improve the safety and efficacy of fibrinolytic therapy, contributing to the continual enhancement of vascular care.
Title : Complete heart block and persistent left SVC: A pacing challenge after AV canal repair
Moataz Taha Mahmoud, Madinah Cardiac Center, Saudi Arabia
Title : Chemical detergent anionic surfactant-inducing dry cardiomyopathy (Yasser's cardiomyopathy) with parallel pupils/CXR phenomenon (Yasser's ophthalmic phenomenon), up-down Yasser's alternance, S1Q3 flat T3 pattern - Dramatic response to honey with possible cardiac regeneration - A case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt
Title : Stabilization of molecular structures in red blood cell membrane by magnetite nanoparticles (ICNB) during storage
Andrey Belousov, Laboratory of Applied Nanotechnology of Belousov and Kharkiv National Medical University, Ukraine